[go: up one dir, main page]

MA53603A - Procédés de modulation de la cytotoxicité à médiation cellulaire dépendante des anticorps - Google Patents

Procédés de modulation de la cytotoxicité à médiation cellulaire dépendante des anticorps

Info

Publication number
MA53603A
MA53603A MA053603A MA53603A MA53603A MA 53603 A MA53603 A MA 53603A MA 053603 A MA053603 A MA 053603A MA 53603 A MA53603 A MA 53603A MA 53603 A MA53603 A MA 53603A
Authority
MA
Morocco
Prior art keywords
antibody
modulation
methods
dependent cell
mediated cytotoxicity
Prior art date
Application number
MA053603A
Other languages
English (en)
Inventor
Scott Kuhns
Alla Polozova
Dong Xiang
Qingchun Zhang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA53603A publication Critical patent/MA53603A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA053603A 2018-09-11 2019-09-10 Procédés de modulation de la cytotoxicité à médiation cellulaire dépendante des anticorps MA53603A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862729971P 2018-09-11 2018-09-11

Publications (1)

Publication Number Publication Date
MA53603A true MA53603A (fr) 2021-07-21

Family

ID=68051968

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053603A MA53603A (fr) 2018-09-11 2019-09-10 Procédés de modulation de la cytotoxicité à médiation cellulaire dépendante des anticorps

Country Status (8)

Country Link
US (1) US20220033511A1 (fr)
EP (1) EP3850006A1 (fr)
JP (2) JP2022500371A (fr)
AU (1) AU2019339895A1 (fr)
CA (1) CA3110530A1 (fr)
MA (1) MA53603A (fr)
MX (1) MX2021002792A (fr)
WO (1) WO2020055900A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116868271A (zh) * 2021-02-19 2023-10-10 基因泰克公司 数据建模中基于相关生物物理学属性来预测功能的方法和系统
JP2024513757A (ja) * 2021-03-23 2024-03-27 グリコエラ アーゲー グリカン媒介タンパク質分解
WO2024220916A1 (fr) * 2023-04-20 2024-10-24 Amgen Inc. Procédés de détermination de teneur relative en glycane non apparié

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
CN1763097B (zh) 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2004063351A2 (fr) 2003-01-09 2004-07-29 Macrogenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
EP4382170A3 (fr) 2009-12-06 2024-09-04 Bioverativ Therapeutics Inc. Polypeptides chimériques et hybrides de facteur viii-fc, et leurs procédés d'utilisation
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
WO2013114167A1 (fr) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Procédé d'obtention d'une composition de glycoforme
WO2013114164A1 (fr) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Procédé d'obtention d'une composition glycoprotéique ayant une concentration accrue d'afucosylation
US10059770B2 (en) 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition
WO2015128793A1 (fr) 2014-02-25 2015-09-03 Dr. Reddy’S Laboratories Limited Procédé pour modifier une composition de glycoprotéine afin d'obtenir une forte teneur en mannose et une galactosylation réduite
WO2015140700A1 (fr) 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Procédé de culture cellulaire
AU2015267047A1 (en) * 2014-05-27 2017-01-05 Academia Sinica Anti-CD20 glycoantibodies and uses thereof
CN114181312A (zh) * 2014-09-10 2022-03-15 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体
JP6698681B2 (ja) 2014-12-01 2020-05-27 アムジエン・インコーポレーテツド 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
ES2875274T3 (es) 2015-11-02 2021-11-10 Hoffmann La Roche Procedimientos de preparación de formas fucosiladas y afucosiladas de una proteína
WO2017134667A1 (fr) 2016-02-02 2017-08-10 Insight Biopharmaceuticals Ltd. Procédés de génération d'anticorps

Also Published As

Publication number Publication date
MX2021002792A (es) 2021-05-12
EP3850006A1 (fr) 2021-07-21
JP2022500371A (ja) 2022-01-04
CA3110530A1 (fr) 2020-03-19
WO2020055900A1 (fr) 2020-03-19
US20220033511A1 (en) 2022-02-03
AU2019339895A1 (en) 2021-03-11
JP2024112905A (ja) 2024-08-21

Similar Documents

Publication Publication Date Title
SG11202106612QA (en) Improved antibody-oligonucleotide conjugate
IL278633A (en) Immunoconjugates
GB201809976D0 (en) Novel formulations
MA53603A (fr) Procédés de modulation de la cytotoxicité à médiation cellulaire dépendante des anticorps
IL290356A (en) Formulations for Resotide
IL289047A (en) Formulations penetrate through the skin
SG11202106898VA (en) M2-defective poxvirus
GB201915094D0 (en) New formulations
GB201904338D0 (en) Fluorouracil-containing formulations
IL284691A (en) formulations
HUE064843T2 (hu) Orális oldat kiszerelés
GB201820413D0 (en) Multiplexed Assay
GB202112727D0 (en) Application for letters patent
EP3964192A4 (fr) Procédé de blanchiment des dents
GB2584304B (en) L-bracket
SG11202010097WA (en) Apixaban formulations
SG11202010792TA (en) Improved pharmaceutical formulations
EP3866846A4 (fr) Procédé d'amélioration de la cytotoxicité à médiation cellulaire dépendant des anticorps (adcc)
GB201910092D0 (en) New formulations
GB201911063D0 (en) Formulations
GB201918725D0 (en) Tooth stressor
GB201905105D0 (en) Formulations
SG11202011823SA (en) Activator-nucleator formulations
GB201819028D0 (en) Butanol-based formulations
PH32019001201S1 (en) Urinal (u4485)